Company intelligence / Profile preview
Atomwise
San Francisco, California, United Statesatomwise.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Atomwise has nominated its first AI-driven development candidate, a TYK2 inhibitor, and plans to submit an IND application in the second half of 2024. Their AI platform has demonstrated a 74% success rate in identifying novel compounds across 318 targets.
- Therapeutic areas
- OncologyImmunologyHematologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Eli LillyBayerGC PharmaHansoh PharmaceuticalsBridge BiotherapeuticsAWSWEKA
Beyond the preview
Go deeper on Atomwise.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atomwise.